PMID- 25516380
OWN - NLM
STAT- MEDLINE
DCOM- 20160101
LR  - 20220409
IS  - 1479-8301 (Electronic)
IS  - 1346-3500 (Linking)
VI  - 15
IP  - 1
DP  - 2015 Mar
TI  - Clinical efficacy of lamotrigine and changes in the dosages of concomitantly used 
      psychotropic drugs in Alzheimer's disease with behavioural and psychological 
      symptoms of dementia: a preliminary open-label trial.
PG  - 32-7
LID - 10.1111/psyg.12085 [doi]
AB  - AIM: We investigated the clinical efficacy and changes in the dosages of 
      concomitantly used psychotropic drugs in lamotrigine therapy in Alzheimer's 
      disease with behavioural and psychological symptoms of dementia (BPSD). METHODS: 
      This study was a 16-week, preliminary open-label trial. The subjects were 40 
      inpatients. The outcome measures assessed were BPSD and cognitive function. BPSD 
      was assessed with the Neuropsychiatric Inventory (NPI) and cognitive function was 
      assessed with the Mini-Mental State Examination. The changes in the dosages of 
      concomitant psychotropic drugs were also assessed. RESULTS: Although the mean 
      changes from baseline NPI scores and the two NPI subscales (anxiety and 
      irritability) were significantly lower within the lamotrigine therapy group, no 
      significant differences were found when we compared the lamotrigine therapy group 
      to the control group. The mean decrease from baseline on the NPI agitation 
      subscale, however, was significantly greater in the lamotrigine therapy group 
      than in the control group (P < 0.05). Furthermore, the mean decrease from 
      baseline in the diazepam-equivalent dose was significantly greater in the 
      lamotrigine therapy group than in the control group (P < 0.05). CONCLUSIONS: The 
      results of this study suggest that the administration of lamotrigine to patients 
      with severe Alzheimer's disease with BPSD may be effective and may make it 
      possible to avoid increasing the dosage of antipsychotic medications prescribed 
      to elderly patients.
CI  - (c) 2014 The Authors. Psychogeriatrics (c) 2014 Japanese Psychogeriatric Society.
FAU - Suzuki, Hidenobu
AU  - Suzuki H
AD  - Department of Psychiatry, Suzuki Clinic, Tokyo, Japan.
FAU - Gen, Keishi
AU  - Gen K
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20141217
PL  - England
TA  - Psychogeriatrics
JT  - Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society
JID - 101230058
RN  - 0 (Psychotropic Drugs)
RN  - 0 (Triazines)
RN  - U3H27498KS (Lamotrigine)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/diagnosis/*drug therapy/psychology
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Lamotrigine
MH  - Male
MH  - Mental Disorders/diagnosis/*drug therapy/psychology
MH  - Mental Status Schedule
MH  - Psychiatric Status Rating Scales
MH  - Psychotropic Drugs/*administration & dosage/adverse effects
MH  - Triazines/*administration & dosage/adverse effects
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - behavioural and psychological symptoms of dementia
OT  - lamotrigine
OT  - psychotropic drugs
EDAT- 2014/12/18 06:00
MHDA- 2016/01/02 06:00
CRDT- 2014/12/18 06:00
PHST- 2014/01/14 00:00 [received]
PHST- 2014/09/01 00:00 [revised]
PHST- 2014/09/11 00:00 [accepted]
PHST- 2014/12/18 06:00 [entrez]
PHST- 2014/12/18 06:00 [pubmed]
PHST- 2016/01/02 06:00 [medline]
AID - 10.1111/psyg.12085 [doi]
PST - ppublish
SO  - Psychogeriatrics. 2015 Mar;15(1):32-7. doi: 10.1111/psyg.12085. Epub 2014 Dec 17.